Phone: Resource Center
Co-Promotion Optimization
AUTHOR: CMK SELECT
A notable pharmaceutical company had agreed to co-promote a drug and, in turn, was obligated to provide a list of contractual deliverables to the partner…CONTINUE READING
Putting Theories Into Practice: Developing Risk Mitigation Strategies
AUTHOR: Kirk Dackow
In a recent article, Risk Management and Disaster Recovery in the Age of COVID-19, we discussed how we can gain valuable risk management insights by…CONTINUE READING
Assessing the Value of Project Management in Medical Affairs
AUTHOR: Jennifer Schaefer
Our previous posts in this series reviewed the history and evolution of Medical Affairs departments in the pharma industry, noting how the growth of these…CONTINUE READING
Project Management: How Medical Affairs Receives Value Every Day
AUTHOR: Jennifer Schaefer
In our prior article, we discussed the history and evolution of Medical Affairs departments, and reviewed how these departments have grown to perform so many…CONTINUE READING
Risk Evaluation and Mitigation Strategies (REMS) B2B Services
AUTHOR: CMK SELECT
The Challenge A pharmaceutical technology company originally created a tool to validate the safety of medications, and while the tool effectively met the initial goal,…CONTINUE READING
Project Management: An Increasingly Important Aspect of Medical Affairs
AUTHOR: Jennifer Schaefer
In prior articles, we have discussed the critical role played by pharmaceutical companies’ Medical Affairs departments, particularly related to product launch preparations and execution. Now…CONTINUE READING
Case for an IT-enabling Business Strategy for companies in the Life Sciences Industry
AUTHOR: D. Douglas
The major trends in the life sciences industry are profoundly affecting the way we all work – from conducting research to distributing products, and everything…CONTINUE READING
The Rising Value of Medical Affairs – Engagement with External Stakeholders (KOLs, TLs, EEs)
AUTHOR: N. Borinshteyn
The ever-evolving relationship between the pharmaceutical industry and its key opinion leaders (KOLs) has been a hot topic for a while, and there are several…CONTINUE READING
Clinical Data Standards
AUTHOR: CMK SELECT
Following the December 17, 2014, FDA binding guidance that all pharma studies starting after December 17, 2016, must conform to a set of FDA-sponsored standards,…CONTINUE READING
Medical Events Compliance
AUTHOR: CMK SELECT
A major pharmaceutical company was in need of a review and approval process to help streamline the planning and execution of its external medical events.…CONTINUE READING
The Continuously Increasing Value of Medical Affairs in Product Launches – Part II
AUTHOR: N. Borinshteyn
As we’ve already begun to look into in Part I of this two-part blog, Medical Affairs teams play a critical role in bringing new treatment…CONTINUE READING